Quarterly report pursuant to Section 13 or 15(d)

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)

v3.8.0.1
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Dec. 31, 2016
Net loss $ (589,983) $ (1,900,736) $ (5,366,946) $ (5,660,755)  
Cash flows from operations     647,216 (1,429,277)  
Asset impairment charges 0 0 0 0  
Cash equivalents 0   0   $ 0
Restricted cash 750,185   750,185   275,611
Cash in excess of FDIC limits 1,038,331   1,038,331    
Allowance for doubtful accounts 500,000   500,000   100,000
Shipping and handling 265,685 115,990 589,687 313,498  
Allowance for customer returns 0   0   0
Inventory, noncurrent 5,110,004   5,110,004   6,478,727
Depreciation expense $ 30,897 48,977 $ 117,744 146,692  
Warrants outstanding 2,100,000   2,100,000    
Research and development $ 179,338 396,238 $ 573,701 879,598  
Advertising expense 152,687 62,912 261,442 210,877  
Unrecognized tax benefits 0   0   $ 0
Germany and The Netherlands [Member]          
Inventory, noncurrent 703,882   $ 703,882    
Options and RSU's [Member]          
Stock options outstanding that are antidilutive     17,668,000    
Consumer Products [Member]          
Research and development 76,520 292,738 $ 181,509 658,817  
Specialty Pharmaceuticals [Member]          
Research and development $ 102,818 $ 103,500 $ 392,192 $ 220,781  
Accounts Receivable [Member] | One Customer [Member]          
Concentration risk percentage     28.00%    
Accounts Receivable [Member] | Two Customers [Member]          
Concentration risk percentage         58.00%